Alnylam to Webcast TTR Investor Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 26, 2024--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, October 9, 2024 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event.
The TTR Investor Day will feature presentations from Alnylam’s management team, including senior leaders from the commercial organization who will discuss launch preparation and highlight the potential for market leadership in ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Alnylam will also be joined by a leading expert in ATTR amyloidosis, Dr. Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Division of Cardiovascular Medicine, Oregon Health & Science University, who will share perspectives on the clinical management of ATTR-CM and unmet medical needs.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran), OXLUMO ® (lumasiran), and Leqvio ® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “ Alnylam P 5 x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
View source version on businesswire.com:https://www.businesswire.com/news/home/20240926873155/en/
CONTACT: Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340Josh Brodsky
(Investors)
617-551-8276
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH
SOURCE: Alnylam Pharmaceuticals, Inc.
Copyright Business Wire 2024.
